Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
10:15am, Tuesday, 03'rd Feb 2026
Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products.
Pfizer beats Q4 profit estimates despite COVID-19 sales decline
10:00am, Tuesday, 03'rd Feb 2026
Pfizer Inc (NYSE:PFE, XETRA:PFE) reported fourth-quarter and full-year 2025 results on Tuesday, exceeding analyst expectations on adjusted earnings even as sales of its COVID-19 products fell. The pha
Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates
08:56am, Tuesday, 03'rd Feb 2026
Pfizer (PFE) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.63 per share a year ago.
Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops
08:50am, Tuesday, 03'rd Feb 2026
On Tuesday, Pfizer Inc. (NYSE: PFE) shared topline data from a mid-stage study for a weight loss drug and reported fourth quarter earnings that beat consensus estimates.
Pfizer says once-a-month weight-loss drug works as it forecasts profit decline
07:28am, Tuesday, 03'rd Feb 2026
Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration's policies on pricing and tariffs.
Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand
07:21am, Tuesday, 03'rd Feb 2026
Pfizer reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline.
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
07:18am, Tuesday, 03'rd Feb 2026
Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can
Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.
07:02am, Tuesday, 03'rd Feb 2026
Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
06:57am, Tuesday, 03'rd Feb 2026
Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products. The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled in
Pfizer beats fourth-quarter profit estimates on strong drug demand
06:50am, Tuesday, 03'rd Feb 2026
Pfizer on Tuesday reported fourth-quarter profit above Wall Street estimates, as sustained demand for older drugs such as blood thinner Eliquis helped offset fading sales of its COVID products.
Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial
06:45am, Tuesday, 03'rd Feb 2026
Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial.
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
06:45am, Tuesday, 03'rd Feb 2026
NEW YORK--(BUSINESS WIRE)--PFE Q4 2025 Earnings Release.
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
11:25am, Monday, 02'nd Feb 2026
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
UK industry body says Sanofi in breach over RSV therapy claims against Pfizer
08:42am, Monday, 02'nd Feb 2026
Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more effective than Pfizer's RSV vaccine, the industry's self-regulatory body said on Monday, resp
3 Headwinds Facing Pfizer in 2026
06:32am, Monday, 02'nd Feb 2026
Pfizer is playing catch-up in the GLP-1 weight-loss space. The drugmaker is getting closer and closer to key patent cliffs.
